Aviragen Vaxart merger to create $264m tablet vaccine firm
Aviragen Therapeutics has called on shareholders to back its proposed merger with oral vaccine delivery firm Vaxart.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs